AbbVie files for US approval of risankizumab

25 April 2018
2019_biotech_test_vial_discovery_big

USA-based AbbVie (NYSE: ABBV) has submitted a Biologics License Application (BLA) to the US Food and Drug Administration for risankizumab, an investigational interleukin-23 (IL-23) inhibitor, being evaluated for treatment of patients with moderate to severe plaque psoriasis.

AbbVie licensed the candidate from privately-held German pharma major Boehringer Ingelheim early in 2016, with an upfront payment $595 million, plus milestones and royalties.

Risankizumab is viewed as a potential competitor to Stelara (ustekinumab), from US healthcare giant Johnson & Johnson (NYSE: JNJ), as well as AbbVie’s own mega-blockbuster Humira (adalimumab).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology